CNS Phase 3 Readout Calendar
Industry-sponsored cns trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularInfectious DiseaseRespiratoryRare DiseaseOphthalmologyDermatologyMusculoskeletalRenalPain
43
Next 6 months
73
Next 12 months
32
Results posted
304
Phase 3 CNS
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 cns trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What cns trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 cns trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which cns trials have already read out?
The "recently read out" section shows Phase 3 cns trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the CNS slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the CNS landscape →
Recently read out & awaiting topline — CNS
· 23Phase 3 cns trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Asset: Fingolimod | Multiple Sclerosis (MS) | Active Not Recruiting | Q1 2026 2026-03-25 | Completed · awaiting
Updated 4mo ago
| NCT04926818 |
| Tasly Pharmaceutical Group Co., Ltd | A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Asset: pimavanserin tartrate | Parkinson's Disease Psychosis | Completed | Q1 2026 2026-02-01 | Completed · awaiting
Updated 5mo ago
| NCT06068465 |
| Novartis Pharmaceuticals | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Asset: Ofatumumab approved dose | Relapsing Multiple Sclerosis (RMS) | Active Not Recruiting | Q1 2026 2026-01-28 | Completed · awaiting
Updated 3mo ago
| NCT06869785 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Asset: Fenebrutinib | Relapsing Multiple Sclerosis | Active Not Recruiting | Q1 2026 2026-01-27 | Completed · awaiting
Updated 5mo ago
| NCT04586010 |
| Lipocine Inc. | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD Asset: LPCN 1154A | Depression, Postpartum +5 | Completed | Q1 2026 2026-01-16 | Completed · awaiting
Updated 5mo ago
| NCT06979544 |
| Eli Lilly and Company | A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine Asset: Galcanezumab | Chronic Migraine | Active Not Recruiting | Q4 2025 2025-12-10 | Completed · awaiting
Updated 5mo ago
| NCT04616326 |
| AbbVie | Open-label Trial in Parkinson's Disease (PD) Asset: Tavapadon | Parkinson Disease | Completed | Q4 2025 2025-12-01 | Completed · awaiting
Updated 7mo ago
| NCT04760769 |
| Amgen | Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine Asset: Erenumab Dose 1 | Migraine | Active Not Recruiting | Q4 2025 2025-11-19 | Completed · awaiting
Updated 7mo ago
| NCT03836040 |
| Eli Lilly and Company | A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Asset: Galcanezumab | Episodic Migraine | Active Not Recruiting | Q4 2025 2025-11-14 | Completed · awaiting
Updated 6mo ago
| NCT03432286 |
| Sanofi | Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Asset: Tolebrutinib | Primary Progressive Multiple Sclerosis | Completed | Q4 2025 2025-11-14 | Completed · awaiting
Updated 6mo ago
| NCT04458051 |
| Novartis Pharmaceuticals | Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Asset: Ofatumumab | Multiple Sclerosis | Completed | Q4 2025 2025-11-04 | Completed · awaiting
Updated 5mo ago
| NCT04788615 |
| VistaGen Therapeutics, Inc. | Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Asset: Fasedienol Nasal Spray | Social Anxiety Disorder | Active Not Recruiting | Q4 2025 2025-10-31 | Completed · awaiting
Updated 8mo ago
| NCT06358651 |
| Biohaven Pharmaceuticals, Inc. | Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder Asset: Troriluzole | Obsessive-Compulsive Disorder | Completed | Q4 2025 2025-10-27 | Completed · awaiting
Updated 6mo ago
| NCT04641143 |
| AbbVie | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine Asset: Atogepant 60 mg | Episodic Migraine +1 | Completed | Q4 2025 2025-10-20 | Completed · awaiting
Updated 7mo ago
| NCT04686136 |
| AbbVie | Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Asset: Cariprazine Flexible Dose | Schizophrenia +2 | Completed | Q4 2025 2025-10-06 | Completed · awaiting
Updated 9mo ago
| NCT04578756 |
| Otsuka Pharmaceutical Development … | A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder Asset: SEP-363856 | Generalized Anxiety Disorder | Completed | Q3 2025 2025-09-26 | Completed · awaiting
Updated 9mo ago
| NCT05729373 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Asset: Fenebrutinib | Multiple Sclerosis, Primary Progressive | Active Not Recruiting | Q3 2025 2025-09-17 | Completed · awaiting
Updated 4mo ago
| NCT04544449 |
| Novo Nordisk A/S | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Asset: Semagludtide | Early Alzheimer's Disease | Completed | Q3 2025 2025-09-16 | Completed · awaiting
Updated 3mo ago
| NCT04777396 |
| Bionomics Limited | Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 Asset: 225 mg BNC210 | Social Anxiety Disorder | Completed | Q3 2025 2025-09-11 | Completed · awaiting
Updated 9mo ago
| NCT06510504 |
| Hoffmann-La Roche | Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Asset: Fenebrutinib | Relapsing Multiple Sclerosis | Active Not Recruiting | Q3 2025 2025-09-05 | Completed · awaiting
Updated 4mo ago
| NCT04586023 |
| Pfizer | A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects. Asset: Rimegepant | Migraine | Completed | Q3 2025 2025-08-25 | Completed · awaiting
Updated 6mo ago
| NCT05810038 |
| Teva Branded Pharmaceutical Produc… | A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Asset: Fremanezumab | Migraine | Completed | Q3 2025 2025-08-15 | Completed · awaiting
Updated 5mo ago
| NCT04530110 |
| BioXcel Therapeutics Inc | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Asset: BXCL501 | Agitation,Psychomotor +5 | Completed | Q3 2025 2025-08-15 | Completed · awaiting
Updated 10mo ago
| NCT05658510 |
Upcoming cns readouts — next 12 months
· 73Industry Phase 3 cns trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | Study on the Efficacy and Safety of QLM1016 in Schizophrenia Asset: 3-6mg QLM1016 | Schizophrenia | Not Yet Recruiting | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 18mo ago
| NCT06799559 |
| UCB Biopharma SRL | A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Asset: Brivaracetam | Childhood Absence Epilepsy +1 | Active Not Recruiting | Q3 2026 2026-08-24 (est.) | Estimated · fresh
Updated 4mo ago
| NCT04666610 |
| Cybin IRL Limited | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" Asset: CYB003 | Major Depressive Disorder | Recruiting | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 3mo ago
| NCT06564818 |
| Cerevance | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications Asset: CVN424 75 mg | Parkinson Disease | Active Not Recruiting | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 3mo ago
| NCT06553027 |
| SK Life Science, Inc. | Cenobamate Open-Label Extension Study for YKP3089C025 Asset: Cenobamate | Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy | Completed | Q3 2026 2026-08 (est.) | Estimated · fresh
Updated 6mo ago
| NCT03961568 |
| Sanofi | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis Asset: Frexalimab | Multiple Sclerosis | Active Not Recruiting | Q4 2026 2026-12-23 (est.) | Estimated · fresh
Updated 5mo ago
| NCT06141486 |
| Sanofi | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis Asset: Frexalimab | Multiple Sclerosis | Active Not Recruiting | Q2 2027 2027-05-06 (est.) | Estimated · fresh
Updated 3mo ago
| NCT06141473 |
| Sanofi | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis Asset: Frexalimab | Multiple Sclerosis | Recruiting | Q3 2027 2027-07-15 (est.) | Estimated · fresh
Updated 3mo ago
| NCT07325292 |
Unlock 65 more cns readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.